Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Design Therapeutics (DSGN) EBITDA Margin (2020)

Design Therapeutics' EBITDA Margin history spans 1 years, with the latest figure at 11700.0% for Q4 2020.

  • On a quarterly basis, EBITDA Margin changed N/A to 11700.0% in Q4 2020 year-over-year; TTM through Dec 2020 was 3685.84%, a N/A change, with the full-year FY2020 number at 3685.84%, changed N/A from a year prior.
  • EBITDA Margin hit 11700.0% in Q4 2020 for Design Therapeutics, up from 11915.0% in the prior quarter.
  • Over the last five years, EBITDA Margin for DSGN hit a ceiling of 438.73% in Q1 2020 and a floor of 11915.0% in Q3 2020.